Companies › Xuanzhu Biopharmaceutical
4 active drug programs in 5 registered trials: 3 Phase 3, 2 Phase 1; Oncology, Gastroenterology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| XZP-3287 | – | Phase 3 | Advanced Breast Cancer | Nov 2029 |
| Anaprazole Proton pump inhibitor (PPI) | – | Phase 3 | Reflux Esophagitis (RE) | – |
| XZB-0004 AXL receptor tyrosine kinase inhibitor | AXL | Phase 1 | Advanced Solid Tumor | Feb 2027 |
| XZP-5955 tablets NTRK and ROS1 fusion inhibitor | NTRK1, NTRK2, NTRK3, ROS1 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07010107 | Anaprazole | Phase 3 | Reflux Esophagitis (RE) | Gastroenterology | Apr 2026 |
| NCT05772455 | XZB-0004 | Phase 1 | Advanced Solid Tumor | Oncology | Feb 2027 |
| NCT04996121 | XZP-5955 tablets | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oncology | Jun 2027 |
| NCT05077449 | XZP-3287 | Phase 3 | Advanced Breast Cancer | Oncology | Nov 2029 |
| NCT05257395 | XZP-3287 | Phase 3 | Advanced Breast Cancer | Oncology | Sep 2030 |
Nuvation Bio Roche Turning Point Therapeutics Bristol-Myers Squibb Dompé Farmaceutici Teligene US Bayer VM Oncology BnH Research Shaanxi Micot Pharmaceutical Technology
Nuvation Bio Avistone Biotechnology Nuvalent Stemline Therapeutics InxMed (Shanghai)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.